A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

Otsuka Pharmaceutical Development & Commercialization, Inc.434 enrolled

Overview

A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.

This is a multicenter, randomized, double-blind, parallel-group, flexible dose, outpatient study evaluating the efficacy and safety of SEP-363856 flexibly dosed (50 - 75 mg/day) versus placebo over an 8-week Treatment Period in subjects with GAD. This study is projected to randomize approximately 434 subjects to 2 treatment groups (SEP-363856 \[50 - 75 mg/day\] or placebo) in a 1:1 ratio. Approximately 30 additional subjects (N = 15 per treatment group) are projected to enroll in the Japan Cohort. Treatment assignment will be stratified by country. Study drug will be taken at approximately the same time each evening at bedtime .

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

434

Conditions

Generalized Anxiety Disorder

Interventions

SEP-363856DRUG

once daily tablet

PlaceboDRUG

once daily tablet

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: (list is not all inclusive) * Male or female subject between 18 to 65 years of age. * Subject meets DSM-5 criteria for a diagnosis of Generalized Anxiety Disorder. * Subject must be willing and able to comply with the study procedures and visit schedule and must be able to understand and follow verbal and written instructions. Exclusion Criteria: (list is not all inclusive) * Subject has DSM-5-based diagnosis of any disorder other than Generalized Anxiety Disorder that was the primary focus of treatment within 12 months before Screening. * Subjects who report an inadequate response to more than 3 antidepressant treatments * Subject is at significant risk of harming self or others based on Investigator's judgment. * Subject has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study. * Female subject who is pregnant, lactating, or plans to get pregnant during the study.

Locations (83)

Outcomes

Primary Outcomes

Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Endpoint

The HAM-A scale consists of 14 items, each defined by a series of symptoms. Each item is rated on a 5-point (0-4) scale, with higher scores indicating greater severity.

Time frame: Week 8

Secondary Outcomes

Change from Baseline in Clinical Global Impression-Severity (CGI-S) score at Endpoint

The CGI-S is a clinician-rated assessment of the subject's current illness state on a 7-point scale, where a higher score is associated with greater illness severity.

Time frame: Week 8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

University of Alabama at Birmingham

Huntsville, Alabama, United States

IMA Clinical Research Phoenix

Phoenix, Arizona, United States

ProScience Research Group

Culver City, California, United States

Excell Research, Inc.

Oceanside, California, United States

Anderson Clinical Research

Redlands, California, United States

California Neuroscience Research, LLC

Sherman, California, United States

Schuster Medical Research Institute

Sherman Oaks, California, United States

Viking Pharmaceutical Trials Inc. dba Viking Clinical Research

Temecula, California, United States

CenExel Collaborative Neuroscience Research

Torrance, California, United States

Pacific Clinical Research Management Group

Upland, California, United States

...and 73 more locations